Verzenio — Revenue
Eli Lilly Verzenio — Revenue decreased by 18.9% to $1.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.3%, from $1.16B to $1.30B. Over 4 years (FY 2021 to FY 2025), Verzenio — Revenue shows an upward trend with a 43.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market penetration, successful clinical adoption, or expanded patient access, while a decrease may signal increased competition, patent expiration, or shifts in oncology treatment standards.
Detailed definition
This metric represents the total gross sales generated from the global commercialization of a specific oncology therapeu...
Peer comparison
Comparable to oncology product revenue lines at major pharmaceutical peers, often benchmarked against market share in specific therapeutic indications.
lly_segment_verzenio_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $341.30M | $335.50M | $404.10M | $469.40M | $588.50M | $617.70M | $807.90M | $750.90M | $926.80M | $1.04B | $1.15B | $1.05B | $1.33B | $1.37B | $1.56B | $1.16B | $1.49B | $1.47B | $1.60B | $1.30B |
| QoQ Change | — | -1.7% | +20.4% | +16.2% | +25.4% | +5.0% | +30.8% | -7.1% | +23.4% | +12.2% | +10.1% | -8.3% | +26.8% | +2.8% | +13.6% | -25.5% | +28.5% | -1.3% | +9.1% | -18.9% |
| YoY Change | — | — | — | — | +72.4% | +84.1% | +99.9% | +60.0% | +57.5% | +68.4% | +41.7% | +39.9% | +43.7% | +31.6% | +35.8% | +10.3% | +11.8% | +7.4% | +3.2% | +12.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's verzenio — revenue?
- Eli Lilly (LLY) reported verzenio — revenue of $1.30B in Q1 2026.
- How has Eli Lilly's verzenio — revenue changed year-over-year?
- Eli Lilly's verzenio — revenue increased by 12.3% year-over-year, from $1.16B to $1.30B.
- What is the long-term trend for Eli Lilly's verzenio — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's verzenio — revenue has grown at a 43.5% compound annual growth rate (CAGR), from $1.35B to $5.72B.
- What does verzenio — revenue mean?
- The total revenue generated from the sales of a specific cancer treatment drug.